EUnetHTA Joint Action 3 (2016-20)

Home  /  Outputs   /  EUnetHTA Joint Action 3 (2016-20) (Page 2)

EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment. PTJA12 addresses ‘Glasdegib indicated for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML)’, submitted by Pfizer. We are delighted that HVB and

Patient group input requested for a new Joint Assessment on a medicinal product for the prevention of vaso-occlusive crises in sickle cell disease (SCD) patients aged 16 years and over. EUnetHTA deems patient involvement very important in the production of

EUnetHTA is pleased to announce that the final project plan, final assessment, comments from the external experts and authors' answers, together with the final abstract and plain language summary for OTCA19 "Screening for osteoporosis in the general population'' are now

EUnetHTA is pleased to announce that the project plan and and comments from external experts for the Other Technologies Collaborative Assessment OTCA22 "Clinical utility of Point-of-care Tests (POCT) D-Dimer and Troponin'' are now available for access. The final assessment report will

PTJA11 addresses 'cefiderocol the for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options’, submitted by Shionogi BV. We are delighted that AIFA and NOMA are authoring this assessment. We will be issuing an

We are pleased to announce that, as of today, a revised version of the methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness”, produced within WP6 B2, has entered the public consultation phase. This

This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active